Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's Sarcoma Family of Tumors

被引:37
作者
Antonio Lopez-Guerrero, Jose [2 ]
Machado, Isidro [1 ]
Scotlandi, Katia [3 ]
Noguera, Rosa [1 ]
Pellin, Antonio [1 ]
Navarro, Samuel [1 ]
Serra, Massimo [3 ]
Calabuig-Farinas, Silvia [1 ]
Picci, Piero [3 ]
Llombart-Bosch, Antonio [1 ]
机构
[1] Univ Valencia, Dept Pathol, Valencia 46010, Spain
[2] Fdn Inst Valenciano Oncol, Mol Biol Lab, Valencia, Spain
[3] IOR, Lab Oncol Res, Bologna, Italy
关键词
Ewing Sarcoma Family of Tumors; cell cycle; p53; 9p21; Ki67; prognosis; SOFT-TISSUE SARCOMAS; PROGNOSTIC-SIGNIFICANCE; P53; GENE; EXPRESSION; DELETION; BONE; PROLIFERATION; TRANSCRIPTS; MUTATIONS;
D O I
10.1002/ijc.25424
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
More than 90% of all Ewing's Sarcoma Family of Tumors (ESFT) exhibit specific chromosomal rearrangements between the EWS gene on chromosome 22 and various members of the ETS gene family of transcription factors. The gene fusion type and other secondary genetic alterations, mainly involving cell cycle regulators, have been shown to be of prognostic relevance in ESFT. However, no conclusive results have been reported. We analyzed the clinicopathological significance of relevant cell cycle regulators in genetically confirmed ESFT. A total of 324 cases were analyzed for the immunohistochemical expression of p53, P21(Waf1/CLp1), p27(Kip1) and Ki67 and the chromosomal alterations of the p53 and 9p21 locus by fluorescent in situ hybridization. We observed that: expression of p53 (p = 0.025), p21(Waf1/CiP1) (p = 0.015) and p27(Kip1) (p = 0.013) was higher in disseminated than in localized disease. Furthermore, a cohort of 217 patients with localized disease was considered for studying the prognosis involvement of these factors on patient follow-up. The median follow-up was 39 months (range: 0.17- 452) with an overall survival (OS) of 55%. Ki67 was expressed in 34% of cases and constituted an independent prognostic factor for progression free survival and OS independently of the type of treatment [hazard ratio of 2.0 (95% Cl: 1.3-3.1; p = 0.003) and 1.9 (95% IC: 13-23; p = 0.007) for progression free survival and OS, respectively, being especially relevant in the group of patients which incorporated radiotherapy in their regimen schedules. In conclusion, this study demonstrates that 1(167 expression constitutes a valuable indicator of poor prognosis in localized ESFT.
引用
收藏
页码:1139 / 1150
页数:12
相关论文
共 46 条
[1]
Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis [J].
Abudu, A ;
Mangham, DC ;
Reynolds, GM ;
Pynsent, PB ;
Tillman, RM ;
Carter, SR ;
Grimer, RJ .
BRITISH JOURNAL OF CANCER, 1999, 79 (7-8) :1185-1189
[2]
Biology of EWS/ETS fusions in Ewing's family tumors [J].
Arvand, A ;
Denny, CT .
ONCOGENE, 2001, 20 (40) :5747-5754
[3]
Ewing's sarcoma family of tumors: Current management [J].
Bernstein, Mark ;
Kovar, Heinrich ;
Paulussen, Michael ;
Randall, R. Lor ;
Schuck, Andreas ;
Teot, Lisa A. ;
Juergens, Herbert .
ONCOLOGIST, 2006, 11 (05) :503-519
[4]
Transcriptional targets of p53 that regulate cellular proliferation [J].
Brown, Lauren ;
Boswell, Sarah ;
Raj, Lakshmi ;
Lee, Sam W. .
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2007, 17 (01) :73-85
[5]
Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT [J].
Brownhill, S. C. ;
Taylor, C. ;
Burchill, S. A. .
BRITISH JOURNAL OF CANCER, 2007, 96 (12) :1914-1923
[6]
COX DR, 1972, J R STAT SOC B, V34, P187
[7]
Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family [J].
de Alava, E ;
Gerald, WL .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :204-213
[8]
EWS-FL11 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma [J].
de Alava, E ;
Kawai, A ;
Healey, JH ;
Fligman, I ;
Meyers, PA ;
Huvos, AG ;
Gerald, WL ;
Jhanwar, SC ;
Argani, P ;
Antonescu, CR ;
Pardo-Mindan, FJ ;
Ginsberg, J ;
Womer, R ;
Lawlor, ER ;
Wunder, J ;
Andrulis, I ;
Sorensen, PHB ;
Barr, FG ;
Ladanyi, M .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1248-1255
[9]
de Alava E, 2000, CANCER-AM CANCER SOC, V89, P783, DOI 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO
[10]
2-Q